What You Should Know
Moderna has selected Salesforce’s Agentforce Life Sciences to serve as its unified, global platform for commercial operations and customer engagement.The platform will consolidate data from SAP, ecommerce, and regional systems to create a single "Customer 360" source of truth for all healthcare provider (HCP) interactions.Field teams will utilize AI-powered agents to automate cycle planning, deliver "next best action" recommendations, and streamline real-time call
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
FDA Announces Real-Time Clinical Trial Pilot Program and Proof-of-Concept Studies with AstraZeneca and Amgen
What You Should Know
The FDA has launched two proof-of-concept (PoC) real-time clinical trials (RTCT) that report endpoints and data signals to the agency as they occur.AstraZeneca is leading a Phase 2 trial (TRAVERSE) for mantle cell lymphoma, while Amgen is conducting a Phase 1b trial (STREAM-SCLC) for small cell lung carcinoma.The initiative aims to eliminate the traditional "hiatus" between clinical phases, moving toward a model of "continuous" trials that reduces regulatory lag.A Request
Read More
Accenture Ventures Invests in Iridius to Scale Compliant-by-Design AI for Life Sciences and Pharmaceuticals
What You Should Know
Accenture Ventures has made a strategic investment in Iridius, an enterprise AI infrastructure company specializing in compliant-by-design solutions for highly regulated industries.The partnership will build end-to-end compliance workflows across the life sciences value chain, covering regulatory submissions, pharmacovigilance, and clinical operations.Iridius technology uses a knowledge engine to translate complex global regulatory standards into machine-readable logic,
Read More
Courier Health Raises $50M to Solve Biopharma’s Data Fragmentation
The Biopharma Bottleneck: Why Courier Health Raised $50M to Fix Fragmented Patient Journeys
What You Should Know
The Funding: New York-based Courier Health has closed a $50 million Series B funding round led by Oak HC/FT, with participation from existing investors Norwest and Work-Bench.The Clinical Disconnect: Despite massive clinical innovation in life sciences, getting patients prescribed to actually start and stay on their medications is a logistical nightmare. According to the 2026
Read More
ViewsML Raises $4.9M for AI-Driven Virtual Biomarker Staining Platform
What You Should Know
The Funding: ViewsML, a company building the computational layer for biomarker discovery, has closed an oversubscribed $4.9M seed round led by Wittington Ventures, with significant strategic participation from Mayo Clinic and Continuum Health Ventures, alongside repeat investors like RiSC Capital and Debiopharm.The Core Technology: ViewsML is building the world’s first virtual biomarker library. Using artificial intelligence, the platform generates per-cell biomarker
Read More
How Pharma Commercial Teams Should Plan Their 2026 Oncology Event Strategy
Given the highly targeted nature of the cancer treatment, most Pharma companies target all their HTA activity on oncology; most, if not all, of their promotional budget on oncology spends go toward conferences and major Oncology events, which serve as the primary interface and promotional activity with target customers, decision makers, and influencers.
Not only do Pharma companies need to simultaneously invest hundreds of thousands of promotional budget dollars on competing mega-events, but
Read More
FDB Launches MedProof MCP to Ground AI Agents in Clinical Drug Knowledge
What You Should Know
The Launch: FDB (First Databank) has announced the general availability of FDB MedProof MCP, the healthcare industry's first Model Context Protocol (MCP) server purpose-built for AI medication decision support.The Protocol: MCP is an emerging, open-source standard that defines how AI agents and Large Language Models (LLMs) interact with external knowledge bases. By creating an MCP server, FDB allows health-tech developers to plug generative AI directly into FDB's
Read More
The Role of Ethical Oversight and Algorithmic Bias in Automated Pharmacovigilance
Pharmacovigilance is changing quietly but fundamentally. You can feel it in the way adverse event reports move faster through systems, in how signals surface earlier, and in how dashboards now carry insights that once took weeks of manual review. Machine learning, natural language processing, and automation have become trusted partners in drug safety operations, handling volumes of data no human team could reasonably manage alone. Yet as these systems take on more responsibility, the role of
Read More
Insilico Medicine and Eli Lilly Form $2.75B AI Drug Discovery Collaboration
Insilico Medicine and Eli Lilly Announce $2.75B AI Drug Discovery Collaboration
- Drug Discovery Collaboration: Insilico Medicine, an AI-native clinical-stage biotech, has signed a massive drug discovery collaboration with pharma giant Eli Lilly.
- The Financials: The deal is structured with a highly lucrative $115M upfront payment to Insilico. With development, regulatory, and commercial milestones, the total deal value could reach $2.75 billion, plus tiered royalties on future
Read More
ImmuneBridge Secures $7.7M to Open Cell Therapy Manufacturing Platform to Biotech Partners
What You Should Know
The Funding & The Pivot: ImmuneBridge has secured a $7.7M second seed round (bringing its total seed funding to nearly $20M) led by NFX, with participation from One Way Ventures, M Ventures, Insight Partners, LongGame Ventures, T.Rx Capital, Healthspan Capital, Sand Hill Angels, and two independent investors. Crucially, the company is using this capital to make its proprietary cell therapy screening and manufacturing platform available to external co-development
Read More
